Literature DB >> 27693645

Comparing 3 guidelines on the management of surgically removed pancreatic cysts with regard to pathological outcome.

Selma J Lekkerkerker1, Marc G Besselink2, Olivier R Busch2, Joanne Verheij3, Marc R Engelbrecht4, Erik A Rauws1, Paul Fockens1, Jeanin E van Hooft1.   

Abstract

BACKGROUND AND AIMS: Currently, 3 guidelines are available for the management of pancreatic cysts. These guidelines vary in their indication for resection of high-risk cysts. We retrospectively compared the final pathologic outcome of surgically removed pancreatic cysts with the indications for resection according to 3 different guidelines.
METHODS: Patients who underwent pancreatic resection were extracted from our prospective pancreatic cyst database (2006-present). The final histopathologic diagnosis was compared with the initial indication for surgery stated by the guidelines of the International Association of Pancreatology (IAP), European Study Group on Cystic tumors of the Pancreas and American Gastroenterological Association (AGA). We considered surgery in retrospect justified for malignancy, high-grade dysplasia, solid pseudopapillary neoplasms, neuroendocrine tumors or symptom improvement. Furthermore, we evaluated the patients with suspected intraductal papillary mucinous neoplasm (IPMN) separately.
RESULTS: Overall, 115 patients underwent pancreatic resection. The preoperative diagnosis was correct in 83 of 115 patients (72%) and differentiation between benign and premalignant in 99 of 115 patients (86%). In retrospect, surgery was justified according to the aforementioned criteria in 52 of 115 patients (45%). For patients with suspected IPMN (n = 75) resection was justified in 36 of 67 (54%), 36 of 68 (53%), and 32 of 54 (59%) of patients who would have had surgery based on the IAP, European, or AGA guidelines, respectively. The AGA guideline would have avoided resection in 21 of 75 (28%) patients, versus 8 of 75 (11%) and 7 of 75 (9%) when the IAP or European guideline would have been applied strictly. Nevertheless, 4 of 33 patients (12%) with high-grade dysplasia or malignancy would have been missed with the AGA guidelines, compared with none with the IAP or European guidelines.
CONCLUSION: Although fewer patients undergo unnecessary surgery based on the AGA guidelines, the risk of missing malignancy or high-grade dysplasia with this guideline seems considerably high.
Copyright © 2017 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27693645     DOI: 10.1016/j.gie.2016.09.027

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  18 in total

Review 1.  The diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas: has progress been made?

Authors:  Jenny Lim; Peter J Allen
Journal:  Updates Surg       Date:  2019-06-07

Review 2.  [Resection of main duct and mixed type IPMN ≥5 mm].

Authors:  G O Ceyhan; F Scheufele; H Friess
Journal:  Chirurg       Date:  2017-11       Impact factor: 0.955

3.  ASO Author Reflections: Improving Identification of Intraductal Papillary Mucinous Neoplasm Patients at Risk-Current Status and the Role of IPMN Molecular Biomarkers.

Authors:  Ajay V Maker
Journal:  Ann Surg Oncol       Date:  2018-10-11       Impact factor: 5.344

Review 4.  Pancreatic Cysts and Guidelines.

Authors:  James J Farrell
Journal:  Dig Dis Sci       Date:  2017-05-20       Impact factor: 3.199

5.  Cyst Fluid Biosignature to Predict Intraductal Papillary Mucinous Neoplasms of the Pancreas with High Malignant Potential.

Authors:  Ajay V Maker; Vincent Hu; Shrihari S Kadkol; Lenny Hong; William Brugge; Jordan Winter; Charles J Yeo; Thilo Hackert; Markus Büchler; Rita T Lawlor; Roberto Salvia; Aldo Scarpa; Claudio Bassi; Stefan Green
Journal:  J Am Coll Surg       Date:  2019-02-19       Impact factor: 6.113

Review 6.  Surgery of Cystic Tumors of the Pancreas - Why, When, and How?

Authors:  Jan G D'Haese; Jens Werner
Journal:  Visc Med       Date:  2018-06-14

7.  Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.

Authors:  Carrie X Cao; Jeremy M Sharib; Amie M Blanco; Dena Goldberg; Paige Bracci; Rita A Mukhtar; Laura J Esserman; Kimberly S Kirkwood
Journal:  J Am Coll Surg       Date:  2019-10-28       Impact factor: 6.113

8.  The validity of the surgical indication for intraductal papillary mucinous neoplasm of the pancreas advocated by the 2017 revised International Association of Pancreatology consensus guidelines.

Authors:  Yusuke Watanabe; Sho Endo; Kazuyoshi Nishihara; Keijiro Ueda; Mari Mine; Sadafumi Tamiya; Toru Nakano; Masao Tanaka
Journal:  Surg Today       Date:  2018-06-30       Impact factor: 2.549

9.  Pancreatic cystic neoplasms in 2018: The final cut.

Authors:  Gabriele Capurso; Giuseppe Vanella; Paolo Giorgio Arcidiacono
Journal:  Endosc Ultrasound       Date:  2018 Sep-Oct       Impact factor: 5.628

Review 10.  Comparison of guidelines for intraductal papillary mucinous neoplasm: What is the next step beyond the current guidelines?

Authors:  Masafumi Nakamura; Yoshihiro Miyasaka; Yoshihiko Sadakari; Kenjiro Date; Takao Ohtsuka
Journal:  Ann Gastroenterol Surg       Date:  2017-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.